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Objective: While patient eligibility for carotid artery stenting (CAS) is well established, the intraoperative technique
remains widely varied. The decision to perform poststent ballooning (PSB) is operator-dependent and often inﬂuenced by
the interpretation of poststent angiography. While visually creating a greater luminal diameter, it is unclear whether PSB
has immediate risks or long-term beneﬁts. The purpose of this report is to determine whether PSB has any effects on
periprocedural hemodynamic stability.
Methods: A retrospective analysis of all patients that underwent CAS between 2005 and 2012 at a tertiary care center was
performed. The primary end point was hemodynamic instability, deﬁned as bradycardia (a heart rate of <60 beats/min)
or hypotension (systolic blood pressure of <90 mmHg) during the intraoperative or postoperative period. Binary logistic
regression model was performed to determine the effect of PSB on the occurrence of hemodynamic instability, adjusting
for patient’s age, sex, hypertension, diabetes mellitus, hyperlipidemia, coronary artery disease, recent myocardial
infarction, previous carotid endarterectomy, high-risk status, and symptomatic status.
Results: A total of 103 (51 men and 52 women) patients underwent placement of a unilateral carotid stent between 2005
and 2012 at our institution. All patients underwent prestent dilatation. However, 70% (n[ 72) underwent PSB whereas
30% (n[ 31) did not. PSB was a signiﬁcant predictor of hemodynamic depression (odds ratio [OR], 3.8; 95% conﬁdence
interval, 1.3-11; P < .01). Symptomatic status, recent myocardial infarction, hyperlipidemia, and coronary artery
disease were associated with a length of stay exceeding 24 hours postoperatively (OR, 6.6; P < .01, OR, 6.1; P < .01,
OR, 5.4; P[ .04, and OR, 9.3; P < .01, respectively). At follow-up, 97% (83/86) stents were patent. Two stent stenoses
occurred in the group that received PSB, while one stent stenosis occurred in the group that did not receive PSB.
Conclusions: PSB increases the risk of intra- or postoperative hemodynamic depression in CAS and might increase the risk
of major adverse cardiovascular events. Given the added complications and the lack of evidence supporting long term
patency, PSB should be only selectively used. (J Vasc Surg 2014;59:756-60.)Stroke is the third leading cause of death and the (SPACE), Endarterectomy Versus Angioplasty in Patients
number one cause of adult disability in the United States.
Carotid artery disease is estimated to contribute 21% of
ischemic strokes.1 Carotid endarterectomy (CEA) has
been established as the gold standard treatment in reducing
stroke risk in patients with symptomatic carotid artery
stenosis ($50%)2,3 and asymptomatic stenosis ($60%).4,5
Carotid artery stenting (CAS) was introduced in the mid-
1970s and continued to evolve as a percutaneous alterna-
tive for high surgical risk patients.6
Over the past few decades, there has been a continued
effort to reﬁne stenting techniques. This is reﬂected in the
steady improvement in the periprocedural major adverse
cardiovascular events (MACE) of carotid stenting. While
the initial results of CAS reported 12.1%7 and 9.92%8 death
or stroke rates, a meta-analysis conducted in 2010 of Stent-
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3S), and International Carotid Stenting Study (ICSS) trials
showed an 8.9% rate of similar outcomes.9 However, newer
trials have demonstrated improvement. In the Carotid
Revascularization Endarterectomy versus Stenting Trial
(CREST), the stroke or death end points occurred at
a 4.8% rate.10 Carotid sinus reactions, exempliﬁed by hypo-
tension or bradycardia are also among the short-term
consequences of CAS.11 The occurrence rate of hemody-
namic depression (HD) has been reported within a wide
range of 19% to 68%,11-15 possibly mirroring the signiﬁcant
variance of the intraoperative technique that may play
a role in HD development.
The most widely practiced steps in CAS include vessel
selection, ﬁlter deployment, predilation, stent deployment,
and poststent ballooning (PSB).16 Despite the lack of
evidence on the beneﬁts of PSB, operators continue to
perform it to provide an optimal cosmetic result. Bussiere
et al found that hemodynamic instability during and after
CAS was observed more often when ballooning was
required.17 Another small study of 18 patients examining
the occurrence of hemodynamic instability during the CAS
procedure found that hypotension or the need for vaso-
pressor treatment was signiﬁcantly more common with
PSB compared with predilation ballooning.13 Also, Spacek
et al concluded that CAS without PSB was safe and had
a low rate of cerebrovascular events and restenosis.18
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and agree on the role of PSB in the development of hypo-
tension and/or bradycardia during or after the procedure.
The purpose of this study is to fully evaluate the effect of
PSB on intraoperative and postoperative HD and examine
the consequence, if any, on MACE and restenosis rates. To
our knowledge, this is the largest study to date that evalu-
ates the inﬂuence PSB has on such outcomes.
METHODS
Patient selection. All of the patients at our center
were referred to us by their primary care physicians or spe-
cialists for evaluation of carotid artery stenosis. If the patient
had >70% stenosis (Society of Radiologists consensus
criteria19) and was a suitable candidate for both CAS and
CEA, and consented, we would randomize them via enroll-
ment in one of two ongoing clinical trials for CAS vs CEA. If
the patient was high risk for surgery (Appendix, online only)
with >70% stenosis, they would be enlisted in one of three
ongoing postmarket stent registries to undergo CAS.
In this study, we retrospectively analyzed a prospec-
tively collected database of all the patients who underwent
CAS at our center (whether enrolled in a trial or not) in the
time period between September 2005 and June 2012.
General stenting technique and patient prepara-
tion. Optimal medical management of diabetes, hyperten-
sion, and dyslipidemia was implemented and the use of
statins was encouraged. Dual antiplatelet therapy including
325 mg of acetylsalicylic acid and 75 mg of clopidogrel was
initiated 5 days prior to the procedure and continued for
4-6 weeks after. Then 81 mg of acetylsalicylic acid only
was given indeﬁnitely.
Duplex ultrasound (DUS) was used to guide in access-
ing the common femoral artery. Systemic heparinization
with an activated clotting time of 250-300 seconds was
maintained throughout the procedure. Micropuncture
sheath and wire were used in the Seldinger technique to
gain access. Next, we exchanged the microsheath for
a 5F sheath and advanced a pigtail catheter over the wire
into the aortic arch.
A 45 degree Left Anterior Oblique view angiography
was performed to elucidate aortic arch type. The pertinent
carotid artery was selected using a 6F 90-cm shuttle select
sheath with its appropriate catheter such as JB1 or VTK
(Cook Inc, Bloomington, Ind). The stenosis was then
conﬁrmed following the North American Symptomatic
Carotid Endarterectomy Trial (NASCET) criteria.20 We
employed rotational angiography where needed. The ﬁlter
was deployed following instructions for use in a straight
segment of the distal internal carotid artery, maintaining
ample distance from intended stent location. Prestent
ballooning was performed in all patients using a 2- to 4-
mm balloon diameter that was 15- to 20-mm long. All
balloon inﬂations during the procedure were slow and
gradual, taking care not to exceed nominal pressure and
then followed by an immediate gradual deﬂation. This
may serve to prevent negative pressure formation, mini-
mizing showering emboli to the brain.We preferentially used 40 mm long stents with a diam-
eter chosen to oversize that of the common carotid by
1 mm. All stents were tapered and deployed using road-
map technology for accurate stent placement. PSB was per-
formed if completion angiography showed greater than
40% residual stenosis that was visually deemed signiﬁcant
by the operator. Anteroposterior and lateral cerebral angio-
grams were performed before and after intervention to
check for embolization.
Hemodynamic measurement. We reviewed all anes-
thesia records and the hospital electronic database for
our CAS patients. HD was deﬁned as bradycardia (a heart
rate of <60 beats/min) or hypotension (systolic blood
pressure [SBP] of <90 mm Hg) during the procedure
and the postoperative period. Intraoperative time period
was considered to start from ﬁrst local anesthetic injection
and end at patient’s exit of the operating room. Postoper-
ative time period ended at patient discharge. Intraopera-
tively, blood pressure was monitored simultaneously
through the arterial sheath and consecutive sphygmoma-
nometer cuff measurements. However, only cuff readings
were used in the analysis to ensure a consistent blood
pressure measurement method throughout the entire
hospital course of the patient. The heart rate was contin-
uously monitored via a multiparameter patient monitor
during the procedure. All patients had a minimum SBP
of 100 mm Hg at the time of insertion of the arterial
sheath.
Postoperatively, all patients were admitted to the
surgical intensive care unit for 24 hours under strict obser-
vation. Heart rate in the surgical intensive care unit was
also monitored by multiparameter patient monitor and
blood pressure was obtained by serial sphygmomanometer
blood pressure measurements.
Patient follow-up. Patient records were reviewed
retrospectively for all selected patients. Eighty-four
percent of patients (86/103) had at least 1 month follow
up. The mean follow-up period was 26 months (standard
deviation 6 18 months). Patients were evaluated by
a neurologist or National Institute of Health Stroke
Criteria-certiﬁed personnel prior to the stenting and on
follow-up appointments. Follow-up visits were scheduled
at 1, 6, 12 months, and yearly thereafter for all patients.
DUS of the carotid arteries was performed on each visit at
our Intersocietal Commission for the Accreditation of
Vascular Laboratories-approved laboratory. Patients with
$70% stenosis were considered restenotic; we followed the
Society of Radiologists Ultrasound consensus criteria for
carotid artery stenosis.19
Statistical analysis. All data and statistical analyses
were performed using the STATA software v. 11 (Stata-
Corp LP, College Station, Tex). Baseline characteristics
were compared between the two cohorts using the Student
t-test for continuous variables and Fisher exact test for cate-
gorical variables. A binary logistic regression model was
constructed to determine which of the measured variables
independently predicts hemodynamic instability. We
adjusted for patient’s age, sex, comorbid conditions,
Table I. Association of poststent ballooning (PSB) with
baseline clinical characteristics
PSB
Yes, No. (%)
72 (70)
No, No. (%)
31 (30) P value
Mean age, years 68 67 .68
Male 37 (51) 14 (45) .67
Symptomatic status 23 (32) 11 (36) .82
Hypertension 64 (89) 24 (77) .14
Diabetes mellitus 28 (39) 5 (16) .04
CAD 44 (61) 18 (58) .83
Recent MI 13 (18) 6 (19) 1.0
Hyperlipidemia 55 (76) 22 (71) .62
COPD 4 (6) 0 (0) .31
High-risk status 51 (71) 26 (84) .22
Previous CEA 20 (28) 16 (52) .03
Beta-blocker use 47 (62) 14 (45) .08
Vasodilator use 13 (18) 6 (19) 1.0
HD 56 (78) 16 (52) .01
Bradycardia alone 27 (38) 5 (16) .04
Hypotension alone 4 (6) 2 (7) 1.0
Both 25 (35) 9 (20) .65
MACE 7 (10) 0 (0) .09
>24 hours length
of stay
26 (36) 6 (19) .11
Stent patency,
n/total
53/55 (96) 30/31 (97) 1.0
No stenosis 44 26 .77
50%-69% stenosis 9 4 .92
>70% stenosis 2 1 1.0
CAD, Coronary artery disease; CEA, carotid endarterectomy; COPD,
chronic obstructive pulmonary disease; HD, hemodynamic depression;
MACE, major adverse cardiovascular events (ie, stroke, death, MI); MI,
myocardial infarction.
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coronary artery disease (CAD), recent myocardial infarc-
tion, previous CEA, high-risk status, and symptomatic
status. A P value of < .05 was considered statistically
signiﬁcant.
RESULTS
A total of 103 (51 men and 52 women) patients under-
went placement of a unilateral carotid stent. Baseline char-
acteristics of patients are presented in Table I. All 103
patients underwent balloon angioplasty before stent
deployment, only 70% (n ¼ 72) underwent PSB. About
one-third (30%; n ¼ 31) did not receive PSB.
The group of patients that underwent PSB was more
often diabetic (39% vs 16%; P < .04). Beta-blockers and
vasodilator medication use was found to be similar between
the two groups (P ¼. 08 and 1.0, respectively). The
average age of each group was almost identical. There
were no other signiﬁcant differences in baseline character-
istics between the two cohorts (Table I). Out of the 103
patients, 72 (70%) experienced HD. Only six patients
had hypotension without bradycardia, while 32 patients
had bradycardia alone. The incidence of MACE in these
two groups was none and one, respectively. There were
34 patients who experienced a combination of hypotension
and bradycardia, and there was a total of six MACE in this
group. Patients who underwent PSB experienced more
incidents of HD either intra- or postoperatively (78% vs
52%; P < .01). Data for follow-up DUS was available for
86 out of 103 patients (84%). Among the group that
received PSB, 76% (55/72) of patients had follow-up reste-
nosis data, while 100% of the no PSB group had similar
data. There was no signiﬁcant difference in restenosis rates
between the two groups (2/55 vs 1/31; P < 1.0).
A binary logistic regression model was constructed to
determine independent variables that predict intra- or post-
operative hemodynamic instability (Table II). Out of all the
variables included, PSB was the only signiﬁcant predictor of
HD adjusted for age, sex, comorbidities, symptomatic
status, previous CEA, and the prior use of beta-blockers
and vasodilators (odds ratio [OR], 3.8; 95% conﬁdence
interval [CI], 1.3-11; P < .01).
One patient experienced a major stroke while another
suffered a minor stroke. Both of these cases occurred in
the cohort that underwent PSB. Moreover, one patient
in the PSB group with severe aortic valve stenosis requiring
aortic valve replacement died in the early postoperative
period after suffering from severe hypotension. The
combined stroke and/or death rate was 2.9% (3/103).
Four patients experienced myocardial infarctions in the
periprocedural period, all of them in the PSB group as
well. The total MACE rate for the study was 6.8% (7/103).
A second regression analysis model was constructed
(Table III) to examine the effect of different variables on
the length of hospital stay (<24 hours vs >24 hours).
Symptomatic status was an independent predictor of the
length of hospital stay exceeding 1 day postoperatively
(OR, 6.6; 95% CI, 1.7-26; P < .01). Additionally, a recentmyocardial infarction, a history of hyperlipidemia and
a history of CAD were also signiﬁcant predictors of
>24 hours hospital stay (OR, 6.1; 95% CI, 1.3-32,
OR, 5.4; 95% CI, 1.1-27, and OR, 9.3; 95% CI,
2.1-41, respectively).
DISCUSSION
Hering (1927) was among the ﬁrst to recognize the
effect neck massage had on hemodynamic changes and
heart rate.21 It was later discovered that the carotid bulb
inﬂuences blood pressure via the medullary vasomotor
nuclei to control cerebral blood ﬂow. Distension at the
bulb decreases peripheral vascular resistance due to cessa-
tion of adrenergic output to the vasculature. Simulta-
neously, the heart rate is lowered due to increased cardiac
parasympathetic stimulation.22
To our knowledge, this is the largest study evaluating
the effect of PSB on HD during and after carotid stenting.
Our study showed an approximate fourfold increase in
risk of HD in patients who receive PSB (OR, 3.8; 95%
CI, 1.3-11; P < .01). Previous research demonstrates
Table III. Binary logistic regression model to predict
secondary outcome: length of stay >24 hours
Unadjusted Adjusteda
OR
(95% CI) P value
OR
(95% CI) P value
PSB 1.4 (0.5-3.7) .54 1.3 (0.3-5.9) .71
Male 0.6 (0.3-1.6) .33 0.5 (0.1-1.8) .28
Age 1.0 (1-1.1) .20 1.1 (1-1.1) .12
High-risk status 1.7 (0.6-5.0) .38 0.8 (0.2-3.7) .75
Symptomatic status 2.9 (1.1-7.6) .03 6.6 (1.7-5.8) <.01
Prior CEA 0.6 (0.2-1.8) .39 0.5 (0.1-2.6) .43
Hypertension 0.9 (0.2-3.0) .80 0.9 (0.2-4.7) .91
Diabetes mellitus 1.34 (0.5-3.6) .55 0.9 (0.2-3.4) .88
CAD 4.2 (1.6-11) <.01 9.3 (2.1-41) <.01
MI 2.2 (0.7-7.0) .18 6.1 (1.3-32) <.01
Hyperlipidemia 2.2 (0.7-7.1) .20 5.4 (1.1-27) .04
CAD, Coronary artery disease; CEA, carotid endarterectomy; CI, conﬁ-
dence interval; MI, myocardial infarction; OR, odds ratio; PSB, poststent
ballooning.
aAdjusted models were adjusted for patients’ age, sex, diabetes, PSB,
hypertension, CAD, chronic obstructive pulmonary disease, previous MI,
previous CEA, high risk for surgery status, and symptomatic status.
Table II. Binary logistic regression model to predict
hemodynamic instability
Unadjusted Adjusteda
OR
(95% CI)b P value
OR
(95% CI) P value
PSB 3.3 (1.2-8.8) .01 3.8 (1.3-11) .01
Sex 1.3 (0.5-3.3) .56 1.3 (0.5-3.7) .6
Age 1.0 (1-1.1) .14 1.1 (1.0-1.1) .08
Beta-blocker use 1.9 (0.7-4.8) .14 1.6 (0.6-4.6) .38
Vasodilator use 0.5 (0.2-1.7) .21 0.4 (0.1-1.3) .11
High-risk status 1.7 (0.6-4.6) .28 2.7 (0.8-9.7) .12
Symptomatic status 0.7 (0.3-1.9) .42 0.4 (0.2-1.2) .11
Hypertension 1.2 (0.3-4.3) .77 1.2 (0.2-6.2) .82
Diabetes mellitus 1.5 (0.6-4.5) .37 2.0 (0.6-6.7) .29
CAD 0.9 (0.4-2.4) .88 0.4 (0.1-1.1) .08
MI 1.8 (0.5-8) .34 2.3 (0.5-10) .27
Hyperlipidemia 0.6 (0.2-1.9) .37 0.5 (0.2-1.9) .32
Previous CEA 1.2 (0.5-3.3) .71 1.7 (0.5-5.2) .37
CAD, Coronary artery disease; CEA, carotid endarterectomy; CI, conﬁ-
dence interval; MI, myocardial infarction; OR, odds ratio; PSB, poststent
ballooning.
aAdjusted models were adjusted for patients’ age, sex, diabetes, PSB,
hypertension, CAD, hyperlipidemia, previous MI, previous CEA, high risk
for surgery status, and symptomatic status.
bRounded to two signiﬁcant ﬁgures.
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and hypertension (SBP >180 mm Hg) prior to CAS24
may increase the risk of developing HD. Gupta et al
showed that patients with persistent HD are at a higher
risk of developing an adverse clinical event such as stroke
or death after CAS.12 It is, therefore, plausible to consider
that certain stenting techniques such as ballooning after
stent deployment could increase the risk of periprocedural
major adverse events.A meta-analysis of SPACE, EVA-3S, and ICSS showed
that periprocedural stroke or death occurred signiﬁcantly
more in the CAS group (8.9%) than the CEA group
(5.8%; P ¼ .0006).9 However, in the CREST trial, CAS
patients experienced a lower periprocedural stroke or death
rate of 4.4% vs 2.3% in the CEA group.10 In fact, the peri-
procedural stroke rates for both procedures in CREST are
the lowest achieved in any randomized controlled trial to
date. In our approach, of all of the 103 patients that under-
went CAS, we had 2.9% periprocedural incidences of stroke
or death.
In CREST, only 6.3% (70/1113) of patients did not
receive PSB compared with 30% (31/103) in our study.
We believe that withholding PSB from a greater number
of patients is one of the factors that contributed to our
lower periprocedural MACE rate (6.8%). The perfor-
mance of careful prestent ballooning in all patients might
have reduced the need for PSB. Other factors include
meticulous patient selection, conservative ballooning
technique (described in the Methods section), use of
transcervical approach in difﬁcult aortic arches, and
employing reverse ﬂow protection for critically stenotic
lesions.
It has been reported in the literature that diabetes
provides a protective effect against the development of
HD during CAS.12 This would be mainly due to the
weakened response to elevations in arterial pressure
among diabetics.25 Despite having more than double
the number of diabetics in our PSB cohort (38% vs
18%; P < .04), we still found a signiﬁcant increase of
HD incidence. The higher prevalence of diabetics in the
PSB group may have masked the true occurrence rate of
bradycardia and/or a low blood pressure among these
patients.
Among the variables examined for their inﬂuence on
hospital length of stay, we found that symptomatic
patients (OR, 6.6; 95% CI, 1.7-26; P < .01), those
with a recent myocardial infarction (OR, 6.1; 95% CI,
1.3-32), those with hyperlipidemia (OR, 5.4; 95% CI,
1.1-27), and those with a history of CAD (OR, 9.3;
95% CI, 2.1-41) were most likely to stay longer than
24 hours in the hospital. These ﬁndings may be explained
by the clustering nature of comorbidities and the possi-
bility of these patients being generally less healthy in
comparison.
Limitations of our study include a small sample size,
lack of randomization, and a disproportional event rate.
In our study, all MACE occurred in the PSB group
(7/72). The fact that we had no events in the group
without PSB did not allow enough power to construct
a logistic regression model to show if there is any rela-
tion between PSB and MACE, nor between HD and
MACE. Additionally, because of the nature of the study,
it is not possible to determine whether the episodes of
HD were the cause or the effect of cardiac adverse
outcomes. Therefore, we believe that the use of PSB in
CAS should be further examined via a large randomized
controlled trial that allows for sufﬁcient power to control
JOURNAL OF VASCULAR SURGERY
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CONCLUSIONS
PSB should be limited and performed with caution
because it signiﬁcantly increases the risk of intra- and postop-
erative HD and may increase the risk of MACE following
CAS. We believe that careful prestent ballooning for all
patients may reduce the need for PSB.
AUTHOR CONTRIBUTIONS
Conception and design: UQ, TO, NE, ES, JW, JF, BP,MM
Analysis and interpretation: NE, ES, MM
Data collection: UQ, MM
Writing the article: UQ, TO, JW, MM
Critical revision of the article: TO, JF, BP, MM
Final approval of the article: UQ, TO, NE, ES, JW, JF, BP,
MM
Statistical analysis: NE, ES, TO
Obtained funding: Not applicable
Overall responsibility: MM
REFERENCES
1. Grau AJ, Weimar C, Buggle F, Heinrich A, Goertler M, Neumaier S,
et al. Risk factors, outcome, and treatment in subtypes of ischemic
stroke. The German stroke data bank. Stroke 2001;32:2559-66.
2. BarnettHJM,TaylorDW,EliasziwM,FoxAJ, FergusonGG,HaynesRB,
et al. Beneﬁt of carotid endarterectomy in patients with symptomatic
moderate or severe stenosis. N Engl J Med 1998;339:1415-25.
3. North American Symptomatic Carotid Endarterectomy Trial Collab-
orators. Beneﬁcial effect of carotid endarterectomy in symptomatic
patients with high-grade carotid stenosis. N Engl J Med 1991;325:
445-53.
4. Endarterectomy for asymptomatic carotid artery stenosis. Executive
Committee for the Asymptomatic Carotid Atherosclerosis Study.
JAMA 1995;273:1421-8.
5. Halliday A, Mansﬁeld A, Marro J, Peto C, Peto R, Potter J, et al.
Prevention of disabling and fatal strokes by successful carotid endar-
terectomy in patients without recent neurological symptoms: rando-
mised controlled trial. Lancet 2004;363:1491-502.
6. Mathias K. [A new catheter system for percutaneous transluminal
angioplasty (PTA) of carotid artery stenoses]. Fortschr Med 1977;95:
1007-11.
7. TrialResults-center.org. WALLSTENT (Alberts) clinical trial
[Internet]. Trialresults-Centerorg. Available at: http://www.trial
resultscenter.org/study7248%2DWALLSTENT%2D%28Alberts%29%
2Ehtm. Accessed June 25, 2013.
8. TrialResults-center.org. CAVATAS-CEA clinical trial [Internet].
Trialresults-Centerorg. Available at: http://www.trialresultscenter.org/
study7249%2DCAVATAS%2DCEA%2Ehtm. Accessed June 25, 2013.
9. Bonati LH, Dobson J, Branchereau A, Chatellier G, Fraedrich G,
Mali WP, et al. Short-term outcome after stenting versus endarterec-
tomy for symptomatic carotid stenosis: a preplanned meta-analysis of
individual patient data. Lancet 2010;376:1062-73.10. Brott TG, Hobson RW, Howard G, Roubin GS, Clark WM, Brooks W,
et al. Stenting versus endarterectomy for treatment of carotid-artery
stenosis. N Engl J Med 2010;363:11-23.
11. Leisch F, Kerschner K, Hofmann R, Steinwender C, Grund M, Bibl D,
et al. Carotid sinus reactions during carotid artery stenting: predictors,
incidence, and inﬂuence on clinical outcome. Catheter Cardiovasc
Interv 2003;58:516-23.
12. Gupta R, Abou-Chebl A, Bajzer CT, Schumacher HC, Yadav JS. Rate,
predictors, and consequences of hemodynamic depression after carotid
artery stenting. J Am Coll Cardiol 2006;47:1538-43.
13. Mendelsohn FO, Weissman NJ, Lederman RJ, Crowley JJ, Gray JL,
Phillips HR, et al. Acute hemodynamic changes during carotid artery
stenting. Am J Cardiol 1998;82:1077-81.
14. Dangas G, Laird JR, Satler LF, Mehran R, Mintz GS, Larrain G, et al.
Postprocedural hypotension after carotid artery stent placement:
predictors and short- and long-term clinical outcomes 1. Radiology
2000;215:677-83.
15. Mylonas SN, Moulakakis KG, Antonopoulos CN, Kakisis JD,
Liapis CD. Carotid artery stenting-induced hemodynamic instability.
J Endovasc Ther 2013;20:48-60.
16. Malik RK, Vouyouka A, Salloum A, Marin ML, Faries PL. Tips and
techniques in carotid artery stenting. J Vasc Surg 2009;50:216-20.
17. Bussière M, Lownie SP, Lee D, Gulka I, Leung A, Pelz DM. Hemo-
dynamic instability during carotid artery stenting: the relative contri-
bution of stent deployment versus balloon dilation. J. Neurosurg
2009;110:905-12.
18. Spacek M, Zimolova P, Veselka J. Carotid artery stenting without post-
dilation. J Intervent Cardiol 2012;25:190-6.
19. Grant EG, Benson CB, Moneta GL, Alexandrov AV, Baker JD,
Bluth EI, et al. Carotid artery stenosis: grayscale and Doppler ultra-
sound diagnosiseSociety of Radiologists in Ultrasound consensus
conference. Ultrasound Q 2003;19:190-8.
20. Ferguson GG, Eliasziw M, Barr HWK, Clagett GP, Barnes RW,
Wallace MC, et al. The North American Symptomatic Carotid
Endarterectomy Trial Surgical results in 1415 patients. Stroke 1999;30:
1751-8.
21. Hering HE. Die Karotissinusreﬂexe auf Herz und Gefässe vom normal-
physiologischen, pathologisch-physiologischen und klinischen Stand-
punkt. Dresden. Leipzig: Th. Steinkopff; 1927.
22. Timmers HJLM, Wieling W, Karemaker JM, Lenders JWM. Dener-
vation of carotid baro- and chemoreceptors in humans. J Physiol
2003;553:3-11.
23. Mlekusch W, Schillinger M, Sabeti S, Nachtmann T, Lang W,
Ahmadi R, et al. Hypotension and bradycardia after elective carotid
stenting: frequency and risk factors. J Endovasc Ther 2003;10:851-9;
discussion: 860-1.
24. Howell M, Krajcer Z, Dougherty K, Strickman N, Skolkin M,
Toombs B, et al. Correlation of periprocedural systolic blood pressure
changes with neurological events in high-risk carotid stent patients.
J Endovasc Ther 2002;9:810-6.
25. Bennett T, Hosking DJ, Hampton JR. Baroreﬂex sensitivity and
responses to the Valsalva manoeuvre in subjects with diabetes mellitus.
J Neurol Neurosurg Psychiatry 1976;39:178-83.Submitted Jul 10, 2013; accepted Sep 16, 2013.
Additional material for this article may be found online
at www.jvascsurg.org.
APPENDIX (online only). High surgical risk criteria
I. Congestive heart failure (class III/IV) and/or known severe left ventricular dysfunction left ventricular ejection fraction <35%.
II. Open-heart surgery within 6 weeks.
III. Recent myocardial infarction (>24 hours and <6 weeks).
IV. Unstable angina (Canadian Cardiovascular Society class III/IV).
V. Synchronous severe cardiac and carotid disease requiring open heart surgery and carotid revascularization.
VI. Requirement of simultaneous or staged cardiac valve surgery.
VII. Severe pulmonary disease.
VIII. Contralateral carotid occlusion.
IX. Contralateral laryngeal palsy.
X. Postradiation treatment to the neck.
XI. Previous carotid endarterectomy recurrent stenosis.
XII. High cervical internal carotid artery lesions or common carotid artery lesions below the clavicle.
XIII. Severe tandem lesions.
XIV. Age $80.
XV. Knowledge of two or more proximal or major diseased coronary arteries with >70% stenosis that have not or cannot be
revascularized.
XVI. Currently on a list for major organ transplantation or is being evaluated for such.
XVII. Spinal immobility with an inability to ﬂex the neck beyond neutral or a kyphotic deformity.
XVIII. Presence of a tracheostomy stoma.
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